Amyris Biotechnologies creates renewable products, focusing on fuels and chemicals. The company is developing renewable fuels that reduce lifecycle (GHG) emissions 80%. The fuel source is special in that it is compatible with current gasoline engines, and can be distributed with existing petroleum infrastructure.
Amyris is also developing semi-synthetic artemisinin, a key ingredient in first-line malaria treatments, in hopes of creating a complementary source of non-seasonal, high-quality, affordable artemisinin. This source would supplement the current botanical supply, offering millions of people infected with malaria the chance to gain consistent and reliable access to lower-cost, life-saving Artemisinin-based Combination Therapies (ACTs). Amyris produces environmentally friendly chemicals for a variety of consumer products and industrial applications currently dependent on petrochemical components.
Amyris was founded in 2003 and is headquartered in Emeryville, US
Amyris Office Locations
Amyris has an office in Emeryville
Emeryville, US (HQ)
100 5885 Hollis St
Amyris Data and Metrics
Amyris Financial Metrics
Amyris's revenue was reported to be $34.2 m in FY, 2015 which is a 21% decrease from the previous period.
USD
Revenue (FY, 2015) | 34.2 m |
Revenue growth (FY, 2014 - FY, 2015), % | (21%) |
Gross profit (FY, 2015) | (3.2 m) |
Gross profit margin (FY, 2015), % | (9%) |
Net income (FY, 2015) | (218.1 m) |
EBIT (FY, 2015) | (148.5 m) |
Market capitalization (27-Jun-2017) | 63.8 m |
Closing share price (27-Jun-2017) | 3.3 |
Cash (31-Dec-2015) | 12 m |
Amyris's current market capitalization is $63.8 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Revenue | 41.1 m | 43.3 m | 34.2 m |
Revenue growth, % | 5% | (21%) | |
Cost of goods sold | 38.3 m | 33.2 m | 37.4 m |
Gross profit | 2.9 m | 10.1 m | (3.2 m) |
Gross profit Margin, % | 7% | 23% | (9%) |
Operating expense total | 122.5 m | 109.9 m | 145.3 m |
EBIT | (119.6 m) | (99.8 m) | (148.5 m) |
EBIT margin, % | (291%) | (231%) | (435%) |
Interest expense | 9.1 m | 28.9 m | 78.9 m |
Interest income | 162 k | 387 k | 264 k |
Pre tax profit | (235.8 m) | ||
Net Income | (234.9 m) | 2.2 m | (218.1 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Cash | 6.9 m | 42 m | 12 m |
Inventories | 9.5 m | 6.5 m | 5.9 m |
Current Assets | 36.9 m | 73.6 m | 35.7 m |
PP&E | 140.6 m | 119 m | 59.8 m |
Total Assets | 198.9 m | 216.2 m | 110.2 m |
Accounts Payable | 6.5 m | 3.5 m | 7.9 m |
Current Liabilities | 37.3 m | 40 m | 76.8 m |
Additional Paid-in Capital | 706.3 m | 724.7 m | 926.2 m |
Retained Earnings | (821.4 m) | (819.2 m) | (1 b) |
Total Equity | (135.8 m) | (125.1 m) | (158.5 m) |
Financial Leverage | -1.5 x | -1.7 x | -0.7 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Net Income | (234.9 m) | 2.2 m | (218.1 m) |
Depreciation and Amortization | 16.6 m | 15 m | 12.9 m |
Accounts Receivable | (4.4 m) | (1.2 m) | 4.9 m |
Accounts Payable | (2.6 m) | (3.2 m) | 4.4 m |
Cash From Operating Activities | (105.9 m) | (84.7 m) | (85.1 m) |
Cash From Investing Activities | (10.3 m) | (9.8 m) | (5.1 m) |
Cash From Financing Activities | 91.2 m | 130.9 m | 61.4 m |
Interest Paid | 3 m | 6.9 m | 9.4 m |
| Y, 2015 | |
|---|---|
Financial Leverage | -0.7 x |
